An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL

We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be conf...

Full description

Bibliographic Details
Main Authors: Purvi M. Kakadia, Ralf Schmidmaier, Andreas Völkl, Irene Schneider, Natalia Huk, Stephanie Schneider, Gerda Panzner, Ulrike Neidel, Barbara Fritz, Karsten Spiekermann, Stefan K. Bohlander
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:Leukemia Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048916300206
Description
Summary:We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be confirmed. The patient was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient expired. Thus, an ETV6/ABL1 fusion positive MPN has the potential to transform very rapidly into ALL.
ISSN:2213-0489